PTC Therapeutics (NASDAQ:PTCT) CEO Sells $192,195.30 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew Klein sold 2,514 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $76.45, for a total value of $192,195.30. Following the completion of the sale, the chief executive officer directly owned 394,453 shares in the company, valued at approximately $30,155,931.85. This represents a 0.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

PTC Therapeutics Stock Up 0.1%

Shares of PTCT traded up $0.06 during midday trading on Monday, hitting $77.59. The company’s stock had a trading volume of 2,631,928 shares, compared to its average volume of 1,795,906. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50. The stock has a market capitalization of $6.23 billion, a price-to-earnings ratio of 9.06 and a beta of 0.49. The company’s fifty day simple moving average is $76.61 and its two-hundred day simple moving average is $62.91.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating the consensus estimate of ($1.19) by $1.39. The business had revenue of $211.01 million for the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.PTC Therapeutics’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.39) earnings per share. On average, research analysts predict that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Institutional Investors Weigh In On PTC Therapeutics

A number of hedge funds have recently modified their holdings of PTCT. Smartleaf Asset Management LLC lifted its stake in PTC Therapeutics by 101.3% in the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares during the last quarter. Optiver Holding B.V. raised its stake in shares of PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 249 shares during the period. Comerica Bank raised its stake in shares of PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 469 shares during the period. IFP Advisors Inc lifted its position in shares of PTC Therapeutics by 68.1% during the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 310 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of PTC Therapeutics by 42.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 295 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Wells Fargo & Company upped their price target on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Morgan Stanley reiterated an “overweight” rating and issued a $90.00 price target on shares of PTC Therapeutics in a research note on Thursday. TD Cowen raised their price objective on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, November 5th. Finally, The Goldman Sachs Group upped their target price on PTC Therapeutics from $44.00 to $50.00 and gave the stock a “sell” rating in a report on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, PTC Therapeutics currently has an average rating of “Hold” and a consensus price target of $77.27.

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Company update: PTC reported unaudited Q4 Sephience global revenue of $92.5M, unaudited 2025 product and royalty revenue of ~ $823M (above guidance), and provided 2026 product revenue guidance of $700–800M (implying ~19–36% YoY growth). Management also reported a strong cash balance of ~ $1.94B as of Dec. 31 — the combination supports near-term growth and a healthy balance sheet. PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
• Neutral Sentiment: Conference transcript: Management’s JPM presentation (transcript) reiterated commercial execution, pipeline priorities, and the company’s strategy for scaling Sephience — helpful for modeling sales cadence and upcoming milestones but containing no major surprises beyond the PR release. PTC Therapeutics Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Negative Sentiment: Insider selling: Multiple senior executives (including the CEO and CFO) sold shares in early January in transactions totaling hundreds of thousands of dollars, which can create short‑term selling pressure or investor concern about insider conviction even if sales may be for diversification or liquidity reasons. Insider Selling: CEO Sells Insider Selling: CFO Sells
• Negative Sentiment: Additional executive stock sales reported across several filings (EVP, VP and others) increase the volume and visibility of insider dispositions in the same window — monitor SEC Form 4s for context on intent and frequency. PTC Therapeutics CEO Sells $396,215.55 in Stock

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.